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Abstract
The pharmacological profile of pitolisant, a histamine H3 receptor antagonist/inverse agonist, indicates that this compound might
reduce body weight and metabolic disturbances. Therefore, we studied the influence of pitolisant on body weight, water and
sucrose intake as well as metabolic disturbances in the high-fat and high-sugar diet-induced obesity model in mice. To induce
obesity, male CD-1 mice were fed a high-fat diet consisting of 40% fat blend for 14 weeks, water and 30% sucrose solution
available ad libitum. Glucose tolerance test was performed at the beginning of week 15. Insulin tolerance was tested the day after.
At the end of study, plasma levels of triglycerides and cholesterol were determined. Pitolisant at dose of 10 mg/kg bw (ip) was
administrated during 14 days, starting from the beginning of week 13. Metformin at dose of 100 mg/kg bw (ip) was used as
reference drug. Mice fed with high-fat diet and sucrose solution showed more weight gain throughout the 12-week period of
inducing obesity. Animals fed with high-fat diet and treated with pitolisant (for the next 14 days) showed significantly less weight
gain than mice from the control group consuming a high-fat feed. In the group treated with pitolisant, glucose levels were
significantly lower than glucose levels of control obese mice after glucose load. The plasma triglyceride levels in pitolisant-
treated mice were significantly lower compared with those in control obese group. In conclusion, pitolisant has a favorable
influence of body weight and improves glucose tolerance and the lipid profile in obese mice.
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Introduction
Histamine H3 receptors serve as presynaptic inhibitory
autoreceptors in the central nervous system; inverse agonists
and antagonists of these receptors increase the synthesis and
release of histamine (Walter and Stark 2012). Histamine itself
might regulate food intake and metabolic disturbances by
influencing the histamine H1, H2 and H3 receptors (Provensi
et al. 2016). Moreover, histamine regulates the release and
interaction of other neurotransmitters such as dopamine, ace-
tylcholine, serotonin, norepinephrine, γ-aminobutyric acid,
glutamate and substance P by affecting histamine H3
heteroreceptors (Feuerstein 2008). Through this pathway, it
controls indirectly, e.g. food intake and motor activity.
Histamine also affects the peripheral metabolism by increas-
ing white adipose tissue lipolysis (Passani et al. 2011).
Histamine H1 and H2 receptor signalling pathways play
important roles in glucose and lipid metabolism, which seems
to be mediated through both central and peripheral pathways.
Histamine H1 receptor signalling is involved in central ner-
vous system and pancreatic tissue to regulate glucose metab-
olism whereas histamine H2 receptors regulate lipid and glu-
cose metabolisms in the liver and skeletal muscle via the
adiponectin system (Wang et al. 2010). In addition, com-
pounds that block histamine H3 receptor activity are capable
of reducing the level of triglycerides in plasma (Malmlöf et al.
2006). In peripheral tissues, H3 histamine receptors are
expressed in neuroendocrine organs and regulate their func-
tions, e.g. in pancreatic β cells in mouse and human and play
an important role in insulin secretion (Nakamura et al. 2014).
Previous studies indicated that H3 histamine receptor li-
gands might exhibit potential anti-obesity activity (Provensi
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et al. 2016). The H3 histamine receptor antagonists (i.e. NNC
38-1049, NNC 38-1202, JNJ-5207852, GT-2394, A-423579;
A-631972, A-331440) supress food intake and cause pro-
found weight loss in various obesity rodent models (Barbier
et al. 2004; Yates et al. 2002; Hancock and Brune 2005;
Malmlöf et al. 2005, 2006). Betahistine, a partial inverse H3
histamine receptor agonist, induced significant weight loss
with minimal adverse events in women under 50 years of
age (Barak et al. 2008) and in animals with obesity after
olanzapine treatment (Lian et al. 2014).
Pitolisant (Fig. 1) is an antagonist/inverse agonist at the H3
histamine receptor (EC50 (human H3 receptor) = 1.5 nM)
(EMA 2015) and might reduce body weight and metabolic
disturbances and be beneficial in the treatment of obesity.
Figure 1 shows the structure. Therefore, in the present study,
we aimed to evaluate the influence of pitolisant on body
weight, water and sucrose intake and metabolic disturbances
in high-fat and high-sugar diet-induced obesity model in mice.
Materials and methods
Animals
Adult male Albino Swiss mice, CD-1, weighing 20–22 g were
used in the study. Animals were kept in environmentally con-
trolled rooms, in standard cages lit by an artificial light for
12 h each day. Animals had free access to food and water,
except for the time of the acute experiment. The randomly
established experimental groups consisted of six mice. All
animal care and experimental procedures were carried out in
accordance with European Union and Polish legislation acts
concerning animal experimentation and were approved by the
Local Ethics Committee at the Jagiellonian University in
Cracow, Poland (Permission No: 135/2013).
Experimental methods
Metabolic disturbance induced with a high-fat/sucrose diet
and influence of pitolisant on body weight
Male CD-1 mice were fed on high-fat diet consisting of 40%
fat blend (Labofeed B with 40% lard, Morawski Feed
Manufacturer, Poland) for 14 weeks, water and 30% sucrose
available ad libitum. Control mice were fed on a standard diet
(Labofeed B, Morawski Feed Manufacturer, Poland) and
drank water only. After 12 weeks, mice with obesity induced
via their diet were randomly divided into three equal groups
that had the same mean body weight and were treated intra-
peritoneally with test compounds at the following doses:
pitolisant 10 mg/kg bw/day (Dudek et al. 2016; Uguen et al.
2013; Zhang et al. 2012) or metformin 100mg/kg bw/day (Al-
Barazanji et al. 2015; Tahara et al. 2011); control group: ve-
hicle =1% Tween 80, 0.35 ml/kg (high-fat/sugar diet + vehicle
= obesity control group) once daily in the morning, between
9:00 and 10:00 AM for 14 days. Control mice (control without
obesity) were maintained on a standard diet, with intraperito-
neal administration of vehicle = 1% Tween 80, 0.35 ml/kg
(standard diet + vehicle = control group). Water and sucrose
were measured daily, immediately prior to administration of
drugs. Animals always had free access to feed, water and
sucrose. Figure 2 shows a scheme that depicts the entire time
course of the experiment.
High-fat feed composition (932 g of dry mass): protein =
193 g, fat (lard) = 408 g, fibre = 28.1 g, crude ash = 43.6 g,
calcium = 9.43 g, phosphorus = 5.99 g, sodium = 1.76 g, sug-
ar = 76 g, magnesium = 1.72 g, potassium = 7.62 g, manga-
nese = 48.7 mg, iodine = 0.216 mg, copper = 10.8 mg, iron =
125 mg, zinc = 61.3 mg, cobalt = 0.253 mg, selenium =
0.304 mg, vitamin A = 15,000 units, vitamin D3 = 1000 units,
vitamin E = 95.3 mg, vitamin K3 = 3.0 mg, vitamin B1 =
8.06 mg, vitamin B2 = 6.47 mg, vitamin B6 = 10.3 mg, vita-
min B12 = 0.051 mg, folic acid = 2.05 mg, nicotinic acid =
73.8 mg, pantothenic acid = 19.4 mg and choline = 1578 mg.
The high-fat diet contained 550 kcal and the standard diet
280 kcal/100 g.
Glucose tolerance test
The test was performed at the beginning of week 15. After
14th administration of the test compound, food and sucrose
were discontinued for 20 h and after this time, glucose toler-
ance was tested. Glucose (1 g/kg bw) was administrated intra-
peritoneally. Blood samples were taken at time points 0 (be-
fore glucose administration) and 30, 60 and 120 min after
administration from tail vein. Glucose level was measured
with glucometer (ContourTS, Bayer, Germany, test stripes:
Fig. 1 Chemical structure of pitolisant Fig. 2 Scheme of the experiment
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ContourTS, Ascensia Diabetes care Poland Sp. z o.o., Poland,
REF: 84239666). The area under the curve (AUC) was calcu-
lated using the trapezoid rule.
Insulin tolerance test
Insulin tolerance was tested the next day after the glucose
tolerance test. After the test, mice had free access to standard
food and water. Also, 3 h before insulin tolerance test, the food
was discontinued. Insulin (0.5 IU/kg bw) was injected intra-
peritoneally and blood samples were taken at time points: 0,
15 and 30 min from tail vein and glucose level was measured
with glucometer (ContourTS, Bayer, Germany, test stripes:
ContourTS, Ascensia Diabetes care Poland Sp. z o.o.,
Poland, REF:84239666). The AUC was calculated using the
trapezoid rule.
Biochemical analysis
The blood was collected after decapitation and then centri-
fuged at 1200 rpm (15min) to obtain the plasma. To determine
cholesterol and triglyceride levels in the plasma, standard en-
zymatic spectrophotometric tests (Biomaxima S.A. Lublin,
Poland, catalogue number: 1-023-0400 or 1-053-0400) were
used. The substrate was decomposed with enzymes appropri-
ate for the relevant product and converted to a coloured com-
pound. Absorbance was measured at a wavelength of 500 nm.
Cholesterol Cholesterol esterase hydrolyses cholesterol esters
to free cholesterol and fatty acids. In the presence of choles-
terol oxidase, free cholesterol is oxidized to cholest-4-en-3-
one and hydrogen peroxide. Hydrogen peroxide reacts with
phenol and 4-aminoantipyrine to form a coloured complex.
The intensity of the colour is directly proportional to the cho-
lesterol concentration.
Triglyceride Lipase hydrolyzes triglycerides to glycerol and
fatty acids. Glycerol in the presence of glycerol kinase and
ATP is phosphorylated to 3-P-glycerol. 3-P-glycerol oxidase
catalyzes the H2O2 formation. Hydrogen peroxide reacts with
4-chlorophenol and 4-aminoantipyrine to form a coloured
complex. The intensity of the colour is directly proportional
to the concentration of triglycerides.
Statistical analysis
The results obtained were analysed using a one-way variance
analysis (ANOVA), followed by a Dunnett post hoc test, with
the significance level set at 0.05 (triglyceride and cholesterol
levels) or a two-way variance analysis (ANOVA), followed by
a Bonferroni post hoc test (changes of body weight), with the
significance level set at 0.05 or by a Multiple t test under the
assumption, that all rows were sampled from populations with
the same scatter (glucose tolerance test, insulin tolerance test).
The results were expressed as the means ± standard error of
the mean (SEM). Graph Pad Prism 6.0 was used for data
analysis.
Drugs, chemical reagents and other materials
Metformin was purchased from Teva Pharmaceuticals
(Poland). Pitolisant was synthesized in the Department of
Technology and Biotechnology of Drugs, Faculty of
Pharmacy, Jagiellonian University Medical College,
Krakow, Poland, according to procedure described by Meier
et al. (2001). Identity and purity of final product were assessed
by NMR and LC-MS techniques.
Pitolisant (10 mg/kg bw) and metformin (100 mg/kg bw)
were suspended in 1% Tween 80. The compounds or vehicle
were administered intraperitoneally (ip) once daily. The vol-
ume of the vehicle or the drug solutions was 10 ml/kg.
Results
Influence of pitolisant on body weight
Mice fed with high-fat diet showedmore weight gain through-
out the 12-week period of inducing obesity. Animals fed with
high-fat diet and treated with pitolisant (next 14 days) showed
significantly less weight gain than mice from the control
group consuming a high-fat diet. From the 10th day of the
pitolisant administration, a statistically significant difference
in body weight between the groups was observed. Metformin,
which served as a positive control, reduced body weight from
the ninth day of administration onward. Results are shown in
Fig. 3.
Influence of pitolisant on water and sucrose intake
There were no significant differences in water intake by ani-
mals between groups fed with high-fat diet. There was no
significant difference in sucrose intake by mice treated with
pitolisant vs. control obese mice fed with high-fat diet.
Significantly less sucrose solution was drunk by animals fed
on high-fat diet and treated with metformin vs. control obese
mice fed with high-fat diet. Results are shown in Fig. 4.
Glucose tolerance and insulin sensitivity
after pitolisant treatment of obese mice
Blood glucose levels of control obese mice fed with high-fat
diet at 60 and 120 min were significantly higher after the
glucose load compared with control mice (fed with standard
feed). In group treated with pitolisant at dose of 10 mg/kg bw
for 14 days, glucose levels were significantly reduced after
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glucose load in obese mice. The blood glucose levels at 60 and
120 min were significantly lower vs. glucose levels of control
obese mice and there were no significant differences among
pitolisant treated group and control group (fed with standard
feed) at 30 and 120 min. Metformin behaved like pitolisant
but the effects of the former drug did not reach a significant
level (Fig. 5a, b). As shown in Fig. 5b, the AUC was also
significantly decreased by pitolisant treatment compared with
obese control group.
In the insulin test (30 min), metformin slightly but signifi-
cantly decreased blood glucose of obese mice whereas
pitolisant only tended to do so (Fig. 5c). If the AUCs are
considered neither drug showed a significant effect (Fig. 5d).
Influence of pitolisant on triglyceride and cholesterol
levels
Hyperlipidemia is a characteristic feature of fat/sugar-induced
obesity in mice. Cholesterol and triglyceride levels were ele-
vated in obese individuals. As shown in Fig. 6a, the plasma
triglyceride levels in pitolisant- and metformin-treated mice
were significantly lower compared to the level in control
obese group. There was no significant difference vs. control
group fed with standard feed. The plasma cholesterol level of
the control obese group tended to be decreased by pitolisant;
metformin led to a significant reduction (Fig. 6b).
Discussion
Although a number of studies with histaminergic ligands in
order to search for a safe and effective drug that might reduce
body weight at obese individuals were conducted (Provensi et
al. 2016), up to date, there was no literature data on pitolisant,
the only histamine H3 receptor inverse agonist that reached the
marked. Therefore, in this study, we performed screening tests
that evaluate the impact of pitolisant on body weight and
metabolic disorders of obese mice.
Our research has shown that 14-day administration of
pitolisant in obese mice can lead to a slight weight decrement
in treated individuals. The loss was not as marked as for the
Fig. 3 Effect of administration of pitolisant on body weight. a Body
weight throughout the administration. b Sum of weight changes.
Results are means ± SEM, n = 6. Multiple comparisons were performed
by two-way ANOVA, Bonferroni post-hoc (a) or one-way ANOVA
Tukey post hoc (b). *p < 0.05, ***p < 0.001 significant between control
mice fedwith fat diet vs. controlmice fed with standard diet; ^^^p < 0.001
significant between control mice fed with standard diet vs. mice treated
with pitolisant; $p < 0.05 significant between control mice fed with fat
diet vs. mice treated with pitolisant; +p < 0.05, ++p < 0.01 and +++p <
0.001 significant between control mice fed with fat diet vs. mice treated
with metformin; #p < 0.05, ##p < 0.01 and ###p < 0.001 significant be-
tween control mice fed with standard diet vs. mice treated with metformin
Fig. 4 Effect of administration of pitolisant on sucrose intake and water
in CD-1 mice. Average of water intake and sucrose. Results are means ±
SEM, n = 6. Comparisons were performed by one-way ANOVA Dunnett
post hoc; +p < 0.05 significant between control mice fed with fat diet vs.
mice treated with metformin
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reference compound, metformin (100 mg/kg bw), but still was
statistically significant. The use of pitolisant for 14 days in
obese mice also significantly improved glucose tolerance. It
can be assumed that increased glucose tolerance may be di-
rectly related to weight loss. However, our research was of a
preliminary character and did not indicated the mechanism of
this action. It might be possible that this compound affects the
secretion of insulin. As it was shown earlier by Nakamura et
al. (2014), histamine H3 receptors are expressed in mouse β
cells and could play a role in insulin secretion and, possibly, β
cell proliferation. H3 histamine receptor inverse agonist JNJ-
5207852 induces insulin secretion from pancreatic β cells and
corrects glucose level.
Animals with induced obesity (administrated with 1%
Tween 80) drank more sucrose solution than animals treated
with metformin or pitolisant; however, the difference for
pitolisant was not significant. Sucrose intake was associated
with improved glucose tolerance for pitolisant as well as insulin
sensitivity in case of metformin treatment. However, our study
did not show any significant improvement in insulin resistance
in obese individuals after the administration of pitolisant.
Obesity caused by high-fat diet coexists with metabolic
disorders such as increased glucose, triglycerides and choles-
terol levels (Dudek et al. 2015a, b; Kotańska et al. 2017). In
our study, obese mice treated with pitolisant had significantly
lower triglyceride levels and slightly (however not significant-
ly) lower plasma levels of cholesterol in comparison to those
in untreated animals. We suggest that improvement of these
metabolic parameters may also be related to the weight loss
that occurred after pitolisant treatment, but might be as well
linked to another mechanism. As has been shown by Dudek et
al. (2016), pitolisant reduced triglyceride levels in mice with
olanzapine-induced disorders. However, obesity was not pres-
ent in these studies, therefore improvement of metabolic pa-
rameters in triglyceride levels might not be associated with
weight reduction.
Fig. 5 Glucose tolerance and insulin sensitivity. a Intraperitoneal glucose
tolerance test (IPGTT). b Area under the curve of IPGTT. c Insulin
tolerance test (ITT). d Area under the curve of the ITT. Results are
means ± SEM, n = 6. Comparisons were performed by two-way
ANOVA, Bonferroni post hoc. *p < 0.05, **p < 0.01 and ***p < 0.001
significant between control mice fed with fat diet vs. control mice fed
standard diet; $p < 0.05 and $$p < 0.01 significant between control mice
fed with fat diet vs. mice treated with pitolisant; ^p < 0.05 significant
between control mice fed with standard diet vs. mice treated with
pitolisant; #p < 0.05 and ##p < 0.01 significant between control mice
fed with standard diet vs. mice treated with metformin; +p < 0.05 signif-
icant between control mice fed with fat diet vs. mice treated with
metformin
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On the other hand, one of the limitations of this study is that
pitolisant was administrated only for 14 days. In fact, longer
administration could show whether the weight reduction is
increasing and becoming important enough to take into ac-
count as an efficient drug for the treatment of obesity. Our
findings are in harmony with the results obtained with a series
of H3 receptor inverse agonists on animals (listed by Provensi
et al. 2016), but it has also been reported that histamine H3
receptor activation yields an anti-obese effect (Yoshimoto et
al. 2006). It is also of interest that pitolisant possesses an
agonistic affect at sigma-1 receptor (EMA 2015) in addition
to its inverse agonistic effect at H3 receptors. The sigma-1
receptor is a target for obesity and eating disorders (Moore
et al. 2017) and might contribute to the overall effect of
pitolisant. However, one has to consider that the inverse ago-
nistic potency of pitolisant at H3 receptors (EC50 (human re-
ceptor) of 1.5 nM) is much lower than its agonistic potency at
sigma-1 receptors (EC50 (human receptor) of 402 nM).
With respect to the use of pitolisant in narcolepsy, the
European Medicines Agency (EMA) states that, based on the
available clinical data, there is no significant effect on body
weight. Weight gain has been seen in 2.9% of the patients
treated with pitolisant, as opposed to 1.3 and 0% of the patients
treated with placebo or modafinil (the standard drug for narco-
lepsy treatment), respectively. However, pitolisant led to
weight loss in very few patients. In some patients, effects on
appetite have also been reported, which were, however, not
always associated with weight gain (and/or vice versa). It is
assumed that pitolisant has no direct effect on weight and that
the changes in weight might have happened due to other
treatment-associated factors (EMA 2015). Uguen et al.
(2013) showed that in rats without metabolic disorders and
obesity, pitolisant did not modify body weight during an 11-
day treatment period with 10 mg/kg ip. However, none of the
studies was related to obese individuals and therefore does not
reflect the influence of pitolisant on bodyweight andmetabolic
parameters under this clinical condition (EMA 2015).
In conclusion, we showed that pitolisant favourably affects
body weight and improves glucose tolerance and the lipid pro-
file in obese mice. However, the level of insulin concentration
after this treatment has not been determined and only such
studies would allow to partially answer the question of the
mechanism of glucose tolerance increment. From the screen-
ing research point of view the test groups were sufficient, but
still small. Testing on larger animals groups would confirm the
information obtained. Therefore, further studies are needed to
elucidate the mechanism of pitolisant action in this regard.
In the present study, we showed that pitolisant may
favourably affect body weight, improve glucose tolerance and
correct lipid profile in obese individuals. Although the results do
not indicate a high efficiency ofweight loss in themouse obesity
model, it might still be considered valuable. Conducted studies
have shown that pitolisant not only does not disturb glucose
tolerance, but it can even improve insulin resistance in obese
animals. This therefore indicates its safety in obese individuals.
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